Anil Nair
Encyclopedia
Anil Nair, MD is researcher on Alzheimer's Disease
Alzheimer's disease
Alzheimer's disease also known in medical literature as Alzheimer disease is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death...

 and neurology
Neurology
Neurology is a medical specialty dealing with disorders of the nervous system. Specifically, it deals with the diagnosis and treatment of all categories of disease involving the central, peripheral, and autonomic nervous systems, including their coverings, blood vessels, and all effector tissue,...

 at Boston University
Boston University
Boston University is a private research university located in Boston, Massachusetts. With more than 4,000 faculty members and more than 31,000 students, Boston University is one of the largest private universities in the United States and one of Boston's largest employers...

.

His areas of interest are new drugs and genetics
Genetics
Genetics , a discipline of biology, is the science of genes, heredity, and variation in living organisms....

 of Alzheimer's Disease. He is the primary investigator for the DHA and IVIG studies which evaluates new drugs for Alzheimer's disease.

Dr. Nair is also investigator for several other Alzheimer's disease drug treatment trials including ADAPT
ADAPT
ADAPT is a grassroots United States disability rights organization with chapters in 30 states. It is known for being part of the militant wing of the disability rights movement due to its history of nonviolent direct action in order to bring attention to the lack of civil rights the disability...

, Flurizan, immunotherapy
Immunotherapy
Immunotherapy is a medical term defined as the "treatment of disease by inducing, enhancing, or suppressing an immune response". Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies. While immunotherapies that reduce or suppress are...

 and IVIG studies in which new medications are being tested for preventing Alzheimer's disease. He is also an investigator in the HOPE study. He also works with the REVEAL Study (Risk Evaluation and Education for Alzheimer's disease), a multi-center project funded by the National Human Genome Research Institute and the NIA to evaluate genetic risk assessment strategies for individuals at risk for Alzheimer's disease by disclosing their APOE information. He is also an investigator with the ADNI trial, which is an NIH funded, 5 year observational study of mild cognitive impairment and early Alzheimer’s disease, by repeated imaging, biological markers and clinical assessments to measure the progression.

External links

The source of this article is wikipedia, the free encyclopedia.  The text of this article is licensed under the GFDL.
 
x
OK